PCSK9 and metabolic syndrome: As per the Institute for Health and Care Excellence (NICE) guidelines, PCSK9 inhibitors alirocumab and evolocumab are recommended for patients with primary hypercholesterolemia or mixed dyslipidemia that is not controlled with statins.